RYBREVANT®/LAZCLUZE® Reports 62.3% Year-on-Year Sales Growth in Q3 2026
Johnson & Johnson reported worldwide sales of $320 million for RYBREVANT® and LAZCLUZE® (lazertinib) in Q3 2026, representing 62.3% year-on-year growth. The combined products generated
